About the Company
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.: Table 1
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGIO News
Agios Pharmaceuticals Inc (AGIO) Stock Experiences -1.06% Monthly Change
AGIO stock has gone up by 1.36%, with a monthly decline of -1.06% and a quarterly surge of 37.64%. The volatility ratio for the week is 3.63%, and the volatility levels for the last 30 days are 3.67% ...
Agios Pharmaceuticals, Inc. (AGIO)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Agios Pharmaceuticals gets grant for phenylketonuria treatment compound
Discover the groundbreaking patent granted to Agios Pharmaceuticals Inc for compounds targeting specific mutations in phenylketonuria patients. Learn more about the innovative Formula I-B-1 compound ...
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases ...
Agios Pharmaceuticals Inc (AGIO) Stock: Evaluating the Market Performance
Smart investors will not be hesitating on this one! Agios Pharmaceuticals Inc (NASDAQ: AGIO)’s stock price has soared by 2.30 in relation to previous closing price of 29.94. Nevertheless, the company ...
Agios Pharmaceuticals Inc AGIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today ...
Agios Pharmaceuticals Inc AGIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Agios Pharmaceuticals Inc
Analysts say investors should buy these undervalued stocks.
Agios Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Agios Pharmaceuticals, Inc. (AGIO)
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript February 15, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Loading the latest forecasts...